PCSK9 and Hyperglycemia: Interestingly, diabetic patients given PCSK9 inhibitors experienced hyperglycaemia more frequently than non-diabetic patients, namely, 11.3% vs 2.1% in the case of evolocumab and 9.9% vs 1.3% in the case of alirocumab.